Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Open accessThe DOI matches its Crossref record; 773 of the 831 references it cites were found in a registry or an index; 177 of the 559 sources its claims cite were checked for support.
Abstract
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders affecting cortisol biosynthesis. Reduced activity of an enzyme required for cortisol production leads to chronic overstimulation of the adrenal cortex and accumulation of precursors proximal to the blocked enzymatic step. The most common form of CAH is caused by steroid 21-hydroxylase deficiency due to mutations in CYP21A2. Since the last publication summarizing CAH in Endocrine Reviews in 2000, there have been numerous new developments. These include more detailed understanding of steroidogenic pathways, refinements in neonatal screening, improved diagnostic measurements utilizing chromatography and mass spectrometry coupled with steroid profiling, and improved genotyping methods. Clinical trials of alternative medications and modes of delivery have been recently completed or are under way. Genetic and cell-based treatments are being explored. A large body of data concerning long-term outcomes in patients affected by CAH, including psychosexual well-being, has been enhanced by the establishment of disease registries. This review provides the reader with current insights in CAH with special attention to these new developments.
Overview
CoChat Summary
TL;DR
This review summarizes current understanding of congenital adrenal hyperplasia (CAH), predominantly 21-hydroxylase deficiency (21OHD), covering steroidogenesis, genetics, diagnosis, management, and long-term outcomes. It emphasizes a phenotypic continuum, newer biomarkers and therapies, and persistent evidence gaps in treatment and surgical care.
Key findings
- 21OHD accounts for approximately 90–99% of CAH; classic CAH incidence is about 1 in 14,000 to 18,000 by newborn screening, while nonclassic (NC) CAH is estimated at ~1 in 200 in the Caucasian population.
- Genotype correlates with the less severely impaired CYP21A2 allele: 96% of individuals with two Group 0 alleles have salt-wasting CAH, whereas 97% of those with at least one Group C allele have NC CAH; residual enzyme activity is ~1–5% in simple virilizing and ~20–50% in NC CAH.
- Long-term sequelae include testicular adrenal rest tumors (TARTs) in males (reported prevalence 14–86%, average 25% in adolescents and 46% in men), adrenal masses in ~20–30% of adults, and increased mortality; adrenal crises caused 42% of deaths in a Swedish cohort, with mean age at death 54.8 years versus 72.8 years in controls.
- Newer concepts include 11-oxo-androgens such as 11-ketotestosterone as biomarkers, the backdoor pathway to dihydrotestosterone, and novel therapies (CRHR1 antagonists, abiraterone, modified-release hydrocortisone, gene/cell-based approaches), though many lack peer-reviewed long-term outcomes.
Methods
- Narrative, multi-authored review resulting from a planned European CAH Symposium postponed due to the COVID-19 pandemic; it covers pathophysiology, diagnostics, management, long-term sequelae, developing-country challenges, and future directions.
- Evidence base is a synthesis of published literature, clinical guidelines (including the 2018 Endocrine Society guideline), registries, observational studies, meta-analyses, and clinical trials; no primary patient cohort or systematic search is described.
- Main analysis is narrative synthesis, with tables and figures summarizing incidence, allele frequencies, treatment dosing, monitoring, and prenatal dexamethasone outcomes.
Limitations
- Stated: there are no large-scale prospective randomized trials for any therapies discussed; evidence is generally low or moderate quality and rests partly on expert opinion, values, and preferences.
- Stated: no evidence-based guidelines for surgical management exist, and there are no studies comparing different feminizing surgery techniques or early versus late surgery; genotype-phenotype correlations are strong but not absolute, and many neuroimaging studies are hindered by small sample size.
- Evident: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or quantitative synthesis; conclusions depend on the cited literature and expert consensus.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
86 Valid · 78 Not valid · 186 Not checked · 76 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Supraphysiological dosages of glucocorticoids similar to those used to treat classic CAH patients may be necessary to suppress adrenal androgen production (426).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Growth
What the sources say
- Disputedcites [426] Livadas, 2019, Management of the female with non-classical congenital adrenal hyperplasia (NCCAH): a patient-oriented approach, Front Endocrinol (Lausanne). sourceExperimental — accuracy not yet measured
In “NCCAH Management From the First Manifestation to the Adult Life” (page unavailable), the paper says glucocorticoids are generally given at replacement, not pharmacological, doses to decrease adrenal androgen production. Its “Management During Childhood” section adds that very high doses are needed to suppress 17-OHP and progesterone, not that supraphysiological doses are necessary to suppress adrenal androgens. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Females do outnumber males in some(12,240,241) although not all (242) retrospective studies in which CAH was clinically diagnosed without neonatal screening.”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Table 7
What the sources say
- Not checked — no full text of the sourcecites [12] Dumic, 2009, Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006, Horm Res. source
- Not checked — no full text of the sourcecites [240] Hird, 2014, No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening, Arch Dis Child. source
- Disputedcites [241] Riedl, 2019, Genotype/phenotype correlations in 538 congenital adrenal hyperplasia patients from Germany and Austria: discordances in milder genotypes and in screened versus prescreening patients, Endocr Connect. sourceExperimental — accuracy not yet measured
Citation (242) is attached to “not all,” offering this study as an example of a retrospectively studied, clinically diagnosed prescreening group without a female majority. The Results (Eligible patients; page unavailable) say the opposite: females made up 64% of the prescreening group. The approximately equal sex distribution was in the screened group, which does not fit that clause. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A single-dose, fixed-sequence study of 8 women given 300 or 600 mg of the CRHR1 antagonist NBI77860 at 2200 (10 PM) showed significant reductions in ACTH and 17OHP over the ensuing 16 hours relative to a control period during which glucocorticoid treatment was withheld (498).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > D. New medical strategies (Figure 5)
What the sources say
- Disputedcites [498] Sanders, 2018, Melanocortin 2 receptor antagonists in canine pituitary-dependent hypercortisolism: in vitro studies, Vet Res Commun. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 2 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plainstates a causen = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Excessive nighttime glucocorticoid administration has potential adverse metabolic consequences (371,382).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Table 7
What the sources say
- Not checked — no full text of the sourcecites [371] Han, 2013, Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia, Clin Endocrinol (Oxf). source
- Partly supportedcites [382] Whitaker, 2014, An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure, Clin Endocrinol (Oxf). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says cortisol is normally low around midnight and that loss of its rhythm is associated with insulin resistance. It also suggests physiological replacement may help metabolic homeostasis. These passages support a potential metabolic concern, but the paper does not specifically state that excessive nighttime glucocorticoid administration has adverse metabolic consequences. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Low expression of CYP21A2 during the second trimester partially explains the high incidence of false-positives in newborn screens for CAH in premature infants (see section IV.A)(159).”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Pattern of CYP21A2 expression
What the sources say
- Could not verifycites [159] Zhou, 1997, Steroid 21-hydroxylase expression and activity in human lymphocytes, Mol Cell Endocrinol. sourceExperimental — accuracy not yet measured
Section 3.1 reports CYP21 expression in cultured lymphoid cells, including cells from CAH patients, but does not examine expression during the second trimester. Searches for premature infants, newborn screening, and false positives found no passage addressing the proposed explanation. (LLM, conf=0.76)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
207 more claims · 72 with their cited sources checked
Create a free account to see all 426 claims and to verify the 50 references still open.
- It may state two separate claims as one. 172
- Probably not a substantial claim. 64
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been reported that heterozygous TNXB mutations may be associated with the mild joint hypermobility form of EDS [1, 15] and that up to 10% of classic SW-CAH patients harboring in compound heterozygosity a TNXB/CYP21A2 genotype tend to demonstrate an extended phenotype termed CAH-X syndrome [1, 31, 32] (Fig. 2).”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been reported that heterozygous TNXB mutations may be associated with the mild joint hypermobility form of EDS [1, 15] and that up to 10% of classic SW-CAH patients harboring in compound heterozygosity a TNXB/CYP21A2 genotype tend to demonstrate an extended phenotype termed CAH-X syndrome [1, 31, 32] (Fig. 2).”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several reports in European, Mediterranean, Middle Eastern, and Chinese populations confirmed a high frequency of the pathogenic IVS2-13A/C > G and found it to comprise 20 to 25% of the CYP21A2 mutant alleles and to translate to the most severe SW forms of the disease when inherited in homozygosity [1, 4, 27, 39–43].”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“When combined with complementary methods such MLPA for copy number analysis, it provides nearly complete diagnostic coverage, identifying up to 98-99% of classical pathogenic alleles in most populations (1, 16, 76).”
From Evolution of molecular diagnostic strategies for 21-hydroxylase deficiency: from classical methods to advanced genomic techniques (2026) · cites this paper as [76]
In the citing paper
“Although CAH is rare, the most common form is caused by steroid 21-hydroxylase deficiency (21-OHD) and is an autosomal-recessive disorder of adrenal steroidogenesis that results from CYP21A2 mutations.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [1]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Sodium chloride supplements 1-2 g (17-24 mEq/day) in infancy”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > Graphical Abstract
Reported 24 · recomputed 34
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“A recent meta-analysis of 48 CAH cases, 34 (71%) described symptomatic improvement after bilateral adrenalectomy but with 34 cases (10%) reporting short-term and 13 cases (27%) long-term adverse outcomes”
§ Congenital adrenal hyperplasia -current insights in pathophysiology, diagnostics and management > D. New medical strategies (Figure 5)
Reported 10 · recomputed 70.833333
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Presence of fetal DNA in maternal plasma and serum
Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., & Wainscoat, J. S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02174-0 · Cited by 3,129
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationConsensus Statement on Management of Intersex Disorders
Lee, P. A., Houk, C. P., Ahmed, S. F., Hughes, I. A., & in collaboration with the participants in the International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology (2006) · Pediatrics · doi:10.1542/peds.2006-0738 · Cited by 2,324
Self-citationBornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Self-citationAromatase Cytochrome P450, The Enzyme Responsible for Estrogen Biosynthesis*
SIMPSON, E. R., MAHENDROO, M. S., MEANS, G. D., KILGORE, M. W., HINSHELWOOD, M. M., GRAHAM-LORENCE, S., AMARNEH, B., ITO, Y., FISHER, C. R., MICHAEL, M. D., et al. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-342 · Cited by 1,537
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Self-citation
Research works printed but not linked: 2
- McCann-Crosby, 2014, Non classic CAH; targets of treatment and transition, Pediatr Endocr Rev., 12, 224
- Auchus, 2012, Abiraterone acetate added to physiologic hydrocortisone dosing safely controls androgen excess in adult women with classical 21-hydroxylase deficiency, Endocr Rev., 33, SUN-LB2
Cited by
Items 201–300 of 554
How to manage puberty and prevent fertility disorders in men with CAH?
der Grinten, H. L. C. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.04.005 · Cited by 4
Self-citationOrtolano, R., Cassio, A., Alqaisi, R. S., Candela, E., Natale, V. D., Assirelli, V., Bernardini, L., Bortolamedi, E., Cantarelli, E., Corcioni, B., et al. (2023) · Children · doi:10.3390/children10091457 · Cited by 4
Robeva, R. N., Andonova, S., Todorov, T., Feyzullova, A., Elenkova, A. P., Кirilov, G., Savov, A. S., Zacharieva, S., & Тодорова, А. (2024) · Biomedicines · doi:10.3390/biomedicines12071528 · Cited by 5
“Pathogenic variants in the CYP21A2 gene might lead to impaired enzyme activity, disturbances in mineral-and glucocorticoid production, and chronic overstimulation of the hypothalamus– pituitary–adrenal axis, resulting in an abundance of androgen precursors [3].”
BackgroundWomen’s response regarding timing of genital surgery in congenital adrenal hyperplasia
Falhammar, H., Holmdahl, G., Nyström, H. F., Nordenström, A., Hagenfeldt, K., & Nordenskjöld, A. (2024) · Endocrine · doi:10.1007/s12020-024-04080-z · Cited by 3
“The far most common cause of CAH is 21-hydroxylase de fi ciency (21OHD) [1].”
Self-citationGenomic complexity and clinical significance of the RCCX locus
Shiryagin, V. V., Deviatkin, A. A., Fateev, O. D., Petriaikina, E. S., Bogdanov, V. P., Antysheva, Z., Volchkov, P., Yudin, S. M., Woroncow, M. V., & Skvortsova, V. I. (2024) · PeerJ · doi:10.7717/peerj.18243 · Cited by 3
Kyle, C. J., Boyle, L. D., Nixon, M., Homer, N. Z. M., Simpson, J., Rutter, A., Ramage, L. E., Kelman, A., Freel, E. M., Andrew, R., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae144 · Cited by 4
Renal pseudohypoaldosteronism type 1—an adult case series including a novel gene variant
Calissendorff, J., & Falhammar, H. (2024) · Endocrine · doi:10.1007/s12020-024-04120-8 · Cited by 4
“The most common cause of salt-wasting in infancy is congenital adrenal hyperplasia (CAH) in its severest form which presents in the neonatal period and girls are also virilized [10].”
Self-citationPrevalence of Psychiatric Comorbidities in Females With Classic Congenital Adrenal Hyperplasia
Khorashad, B. S., Kaabi, O., Gardner, M., Getahun, D., Goodman, M. G., Lash, T. L., Lee, P. A., May, J. A., McCracken, C., Muzik, M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae831 · Cited by 3
Self-citationTreatment and Prevention of Adrenal Crisis and Family Education
Çamtosun, E., & Sangün, Ö. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-12-s · Cited by 9
“It is known that approximately 50 mg of HC is equivalent to 100 mcg fludrocortisone (25).”
Eitel, K. B., & Fechner, P. Y. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae710 · Cited by 8
Case Report: A Novel Mutation Leading to 11-β Hydroxylase Deficiency in a Female Patient
Özbaş, B., Demir, M., Dursun, H., Şahin, İ. O., Hacıoğlu, A., Karaca, Z., Dündar, M., & Ünlühızarcı, K. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666221007145410 · Cited by 3
“Deficiencies in enzymes (21 hydroxylase, 11βhydroxylase, 17α-hydroxylase, 3β-hydroxysteroid dehydrogenase type 2, steroidogenic acute regulatory protein, P450 cholesterol side-chain cleavage enzyme and P450 oxidoreductase) necessary for steroid biosynthesis lead to CAH, which is one of the most common genetic diseases…”
BackgroundStachanow, V., Neumann, U., Blankenstein, O., Alder‐Baerens, N., Bindellini, D., Hindmarsh, P. C., Ross, R. J. M., Whitaker, M. J., Melin, J., Huisinga, W., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16030464 · Cited by 3
Korula, S., Chapla, A., Ravichandran, L., & George, A. (2023) · Journal of Pediatric Endocrinology and Diabetes · doi:10.25259/jped_4_2023 · Cited by 4
Caring for Patients With Congenital Adrenal Hyperplasia Throughout the Lifespan
Zwayne, N., Chawla, R., & van Leeuwen, K. D. (2023) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005263 · Cited by 3
Ahn, C. H., Shim, J., Jang, H. N., Lee, Y. A., Lee, S., Choi, M. H., & Kim, J. H. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106374 · Cited by 4
Gabriele, A., Chierto, E., Gino, S., et al. (2023) · Forensic Science International Synergy · doi:10.1016/j.fsisyn.2023.100440 · Cited by 3
Francisco, A., Yılmaz, A. M., Navarro, C. D. C., Önder, A., Yıldız, M., Demirkol, Y. K., Karademir-Yilmaz, B., menevse, T. S., Güran, T., & Castilho, R. F. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae011 · Cited by 4
Ravichandran, L., Paul, S., Aaron, R., Asha, H., Mathai, S., Simon, A., Danda, S., Thomas, N., & Chapla, A. (2024) · Endocrine · doi:10.1007/s12020-024-03747-x · Cited by 6
Prevalence and Clinical Management of Adrenal Tumour-Related Hyperandrogenism: A Narrative Review
Medenica, S., Živanović, D., Milardi, D., Bruno, C., Batkoska, L., Traini, E., & Pontecorvi, A. (2024) · Life · doi:10.3390/life14030360 · Cited by 4
Khorashad, B. S., Kaabi, O., Gardner, M. D., Getahun, D., Goodman, M. G., Lash, T. L., Lee, P. A., McCracken, C., May, J., Muzik, M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae720 · Cited by 6
Self-citationLiu, J., Tian, H., Jin, X., Wang, Y., Zhang, Z., Li, M., Dai, L., Zhang, X., & Jiang, L. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01748-5 · Cited by 3
“Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive genetic disorders of adrenal steroid biosynthesis, in over 90% of cases due to 21-hydroxylase deficiency (21-OHD) [1].”
BackgroundAdrenal adenoma secreting 17-hydroxyprogesterone mimicking non-classical 21-hydroxylase deficiency
Woźniak, B., Leszczyńska, D., Szatko, A., Nowak, K., Samsel, R., Siejka, A., Papierska, L., Zgliczyński, W., Falhammar, H., & Glinicki, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499836 · Cited by 7
Self-citationHigh carrier frequency of a nonsense p.Trp230* variant in HSD3B2 gene in Ossetians
Makretskaya, N., Kalinchenko, N. Y., Tebieva, I. S., Ionova, S. A., Zinchenko, R. A., Владимирович, М. А., & Tiulpakov, A. N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1146768 · Cited by 3
“To date, 7 distinct clinical forms of CAH and the corresponding genes are recognized, namely: lipoid adrenal hyperplasia, STAR (OMIM #201710); deficiency of cholesterol side-chain cleavage enzyme, CYP11A1 (OMIM #613743); deficiency of 3b-hydroxysteroid dehydrogenase, HSD3B2 (OMIM #201810); deficiency of 17a-hydroxylas…”
BackgroundMiranda, M. C. D., Oliveira, A. C. M. D., Soares, G. J., Batatinha, J. A. P., Latronico, A. C., Mendonca, B. B., & Bachega, T. A. S. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1770274 · Cited by 2
“When combined with complementary methods such MLPA for copy number analysis, it provides nearly complete diagnostic coverage, identifying up to 98-99% of classical pathogenic alleles in most populations (1, 16, 76).”
Zhang, Y., & Yuan, Y. (2023) · Medicine · doi:10.1097/md.0000000000036727 · Cited by 3
“[1] 17OHD is caused by mutation of the coding gene CYP17A1, which belongs to the member of 17 subfamily of cytochrome P450 superfamily (P450c17).”
BackgroundStuckey, B. G. A., Dedic, D., Zhang, R., Rabbah, A., Turcu, A. F., & Auchus, R. J. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae077 · Cited by 3
“The intact adrenal in 21OHD directly and indirectly (via liver metabolism) produces several steroids with mineralocorticoid and glucocorticoid activity [ 14].”
BackgroundSelf-citationChen, S., Wu, L., Ma, X., Guo, L., Zhang, J., Gao, H., & Zhang, T. (2024) · Medicine · doi:10.1097/md.0000000000040297 · Cited by 4
Kamrath, C., & der Grinten, H. L. C. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0440 · Cited by 3
“The typically elevated steroid precursors in patients with 21OHD are 17OHP and 21 deoxycortisol (21DF) (Figure 1) [1, 3, 12].”
Self-citationChai, Q., Yang, W., Zhou, Y., Zhu, G., Dong, H., Huang, B., & Jin, L. (2025) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-025-03491-9 · Cited by 4
Under the hood: vulvar anatomy and pathology with a focus on MRI
Golden, E., Cooke, S. B., Butler, E., et al. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05179-1 · Cited by 2
“At the highest stages, patients can have a common channel urogenital sinus for both the urethra and vagina [24] (Fig.”
EndoCompass project: research roadmap for adrenal and cardiovascular endocrinology
Husebye, E. S., Assié, G., Krone, N. P., Achermann, J. C., Altieri, B., Amar, L., Castro, M. A., Mj, B., Casey, R. T., der Grinten, H. L. C., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf063 · Cited by 2
Self-citationFedorova, O., & Falhammar, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1693063 · Cited by 2
Self-citationLiu, Y., Cai, S., Zhang, T., Kong, X., Zhou, J., Chen, B., & Li, Z. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120700 · Cited by 2
Crinecerfont: CRF1R Antagonist Approved for Treatment of Congenital Adrenal Hyperplasia
Yuan, L. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251396594 · Cited by 3
Gavriilidis, E., Antoniadou, C., Dimopoulou, G., Papadimitriou, E., Bakola, S.-A., Papagoras, C., Skendros, P., & Tsilingiris, D. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100429 · Cited by 3
“Congenital adrenal hyperplasia and syndrome of apparent mineralocorticoid excess typically present in early childhood and were considered unlikely due to the late onset of hypokalemia [3,4].”
Exploration of the potential of genomic editing in the treatment of congenital adrenal hyperplasia
Graves, L. E., Christina, S., Mullany, K., Alexander, I. E., & Falhammar, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1719376 · Cited by 2
“%) copy number variants (9, 28, 29).”
InfluentialSelf-citationNeonatal Screening for Congenital Adrenal Hyperplasia in Guangzhou: 7 Years of Experience
Jia, X., Xie, T., Jiang, X., Tang, F., Tan, M., Chen, Q., Liu, S., Huang, Y., & Li, T. (2025) · International Journal of Neonatal Screening · doi:10.3390/ijns11040116 · Cited by 3
Hamidi, O., Auchus, R. J., Correa, R. R., Levine, A. C., Wierman, M. E., Hartzell, A. L., Lin, V. H., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag147 · Cited by 4
Self-citationTosun, B. G., Erçetin, A. N., Turan, S., Bereket, A., Arğa, K. Y., & Güran, T. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag237 · Cited by 1
A molecular cell atlas of endocrine signaling in human neural organoids
Matassa, G., Rigoli, M. T., Castaldi, D., Valenti, A., Lessi, M., Caporale, N., Stucchi, S., Muda, B., Nagni, R., Mainardi, L., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100077 · Cited by 7
Leukocyte Telomere Length in Children With Congenital Adrenal Hyperplasia
Raftopoulou, C., Abawi, O., Sommer, G., Binou, M., Paltoglou, G., Flück, C. E., van den Akker, E. L. T., & Charmandari, E. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac560 · Cited by 2
Self-citationBesci, Ö., Erbaş, İ. M., Küme, T., Acinikli, K. Y., Abacı, A., Böber, E., & Demir, K. (2022) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2021.2021-9-17 · Cited by 4
Dermatologic care of patients with differences of sex development
Gold, S., Huang, C. Y., Radi, R., Gupta, P., Felner, E. I., HAW, J. S., Childress, K. J., Sokkary, N. A., Tangpricha, V., Goodman, M. G., et al. (2023) · International Journal of Women’s Dermatology · doi:10.1097/jw9.0000000000000106 · Cited by 2
Dubinski, I., Pozza, S. B., Bidlingmaier, M., Hawley, J. M., Keevil, B. G., Kunz, S. L., Nowotny, H. F., Reisch, N., Schiergens, K. A., Tschaidse, L., et al. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0027 · Cited by 3
Self-citationLinear growth in children and adolescents with congenital adrenal hyperplasia
Savage, M. O. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001361 · Cited by 3
Hall, M.-F. E., Kremen, J., Boskey, E. R., Tulimat, S., Staffa, S. J., & Grimstad, F. W. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0158 · Cited by 2
Qin, Y., Su, H., Jing, X., Li, S., Ji, X., Zhang, Z., Wang, Y., Huang, X., Xue, T., Wu, X., et al. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2373741 · Cited by 2
Approach to the Child and Adolescent With Adrenal Insufficiency
Patti, G., Zucconi, A., Matarese, S., Tedesco, C., Panciroli, M., Napoli, F., Iorgi, N. D., & Maghnie, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae564 · Cited by 5
The Development of Legal Rights for Intersex Persons: Part I: The Diversity of Intersex Conditions
Felthous, A. R., & Kahlon, C. K. (2024) · Behavioral Sciences & the Law · doi:10.1002/bsl.2705 · Cited by 3
Liimatta, J., Sauter, K., du Toit, T., Schaller, A., l’Allemand, D., & Flueck, C. E. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luae245 · Cited by 3
Unmasking primary aldosteronism: Transforming disease management with advanced steroid profiling
Zhong, J., Paljor, T., Yu, S., & Qiu, L. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120186 · Cited by 2
Barra, C. B., Sena, G. S., Oliveira, H. P., Gonzaga, A. L. A. C. D. P., Araújo, R. F., Villela, T. R., Mantovani, R. M., Januário, J. N., & Silva, I. N. (2025) · Jornal de Pediatria · doi:10.1016/j.jped.2024.10.012 · Cited by 3
Santis, E. M., Campos-Martorell, A., Fernández‐Álvarez, P., Oriola, J., Yeste, D., Pérez, V., & Clemente, M. (2025) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2025.503747 · Cited by 6
Pulungan, A. B., Puteri, H. A., Waladhiyaputri, V., Chandra, A. P., Ratnasari, A. F., Idaayen, F., Fadiana, G., Armstrong, K. E., & Utari, A. (2025) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2024-0051 · Cited by 3
Self-citationLawrence, N., Bacila, I. A., Tonge, J. J., Dawson, J., Collins, G. S., Lang, Z.-Q., Bryce, J., Alimussina, M., Chen, M., Ali, S., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf060 · Cited by 5
Self-citationLiu, Y., Gang, X., Gao, Y., & Wang, G. (2025) · Endocrine · doi:10.1007/s12020-025-04237-4 · Cited by 2
“This correlation aligns mechanistically with the pathophysiology of CAH, where a reduction in the functional CYP21A2 enzyme leads to impaired cortisol synthesis, in increased ACTH secretion and subsequent androgen production [2].”
Laparoscopic management of transverse testicular ectopia with spermatic cord fusion: a case report
Gu, C., Sun, J., Ding, L., et al. (2025) · AME Case Reports · doi:10.21037/acr-24-288 · Cited by 2
White, P. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-06231-5_25 · Cited by 2
Self-citationNordenström, A., & Falhammar, H. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100616 · Cited by 2
Self-citationSpecialty grand challenge in adrenal endocrinology
Falhammar, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1237733 · Cited by 2
“The incidence of classic CAH is around 1/15000 according to neonatal screening programs (11).”
BackgroundSelf-citationBanyeh, M., Kangkpi, T., Bani, S. B., Zogli, K. E., Tanko, M. M., Atuahene, P. E., Iddrisu, A. Y., Ekor, C., Akoto, E. O., & Amidu, N. (2023) · Health Science Reports · doi:10.1002/hsr2.1547 · Cited by 5
Li, J., Zhang, F., Xu, M., Qiu, H., Zhou, C., Li, L., & Qin, L. F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1216767 · Cited by 2
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Liang, M. C., Kokorowski, P. K., Tseng, T., Koppin, C. M., & Geffner, M. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-14881-1_59 · Cited by 2
Ertörer, M. E., Anaforoğlu, İ., Yılmaz, N., Akkuş, G., Turgut, S., Ünlühızarcı, K., Selçukbiricik, Ö. S., Merdin, F. A., Karakılıç, E., Koroglu, E. P., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03799-z · Cited by 3
Horn, G., Demel, T., Rothmiller, S., Amend, N., & Worek, F. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2361879 · Cited by 4
Çetinkaya, S. Ç. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1332962 · Cited by 2
Monlong, J., Chen, X., Barseghyan, H., Rowell, W. J., Negi, S., Nokoff, N., Mohnach, L. H., Hirsch, J. A., Finlayson, C. A., Keegan, C. E., et al. (2025) · medRxiv · doi:10.1101/2025.02.07.25321404 · Cited by 3
Self-citationMapping endocrine networks by stable isotope tracing
Andrew, R., & Stimson, R. H. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100381 · Cited by 1
Patient and Parent Perspectives on Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia
Nebesio, T. D., Kim, M. S., Szymanski, K. M., Kokorowski, P. K., Geffner, M. E., Eugster, E. A., & on behalf of the Life with Congenital Adrenal Hyperplasia Study Group (2023) · Hormone Research in Paediatrics · doi:10.1159/000529211 · Cited by 1
Kaneto, H., Isobe, H., Sanada, J., Tatsumi, F., Kimura, T., Shimoda, M., Nakanishi, S., Kaku, K., & Mune, T. (2023) · Diagnostics · doi:10.3390/diagnostics13030505 · Cited by 2
Current and future perspectives on clinical management of classic 21-hydroxylase deficiency
Yogi, A., & Kashimada, K. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej23-0075 · Cited by 2
Novel homozygous mutation in SCNN1A gene in an Iranian boy with PHA1B
Saffari, F., Bahadoran, E., Homaei, A., et al. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0505 · Cited by 1
Genotype and Phenotype of 21-Hydroxylase Deficiency: A Single Center Experience from Western India
Karlekar, M. P., Barnabas, R., Sarathi, V., Lila, A. R., Arya, S., Hegishte, S. C., Bhandare, V. V., Memon, S. S., Patil, V. A., Bandgar, T., et al. (2024) · Indian Pediatrics · doi:10.1007/s13312-024-3296-8 · Cited by 2
Treatment and Follow-up of Non-stress Adrenal Insufficiency
Buğrul, F., & Murat, N. Ö. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-23-s · Cited by 5
“Since glucocorticoid absorption and clearance show individual differences, individualization of dose adjustment according to need, with intermittent monitoring after initial doses would be the most appropriate approach (2,3,14).”
InfluentialSantis, E. M., Campos-Martorell, A., Fernández‐Álvarez, P., Oriola, J., Yeste, D., Pérez, V., & Clemente, M. (2025) · Anales de Pediatría · doi:10.1016/j.anpedi.2024.503747 · Cited by 1
Has the Era of Individualized Intrauterine Treatment for Congenital Adrenal Hyperplasia Arrived?
Fu, X., Xia, Y., Li, S., Zhao, Z., Kong, L., Zhu, J., Li, H., Wu, S., Wu, D., & Kong, X. (2025) · Prenatal Diagnosis · doi:10.1002/pd.6747 · Cited by 1
Congenital Adrenal Hyperplasia: A Clinical Review
Harris, D. E. (2025) · Universal Library of Clinical Nursing · doi:10.70315/uloap.ulcnu.2025.0201002 · Cited by 1
Cutoff levels for newborn screening of 21-OH deficiency in a Brazilian metropolitan area
Gameleira, K. P. D., Thomas, J. D. V., de Araújo, V. G. B., Bolognani, C. V., Fernandes, S. E. S., & Amorim, F. F. (2025) · Jornal de Pediatria · doi:10.1016/j.jped.2025.03.003 · Cited by 1
“3,12,13 In this study, from a database of a metropolitan Brazilian NHS program, the authors compared an N17OHP cutoff level adjusted for BW with Hayashi ’ s study 11 and a 17OHP cutoff value (cid:1) 20 ng/mL for all BW. CAH-21OHD is a rare genetic disease characterized by multiple hormonal…”
Germ cell and other tumors in individuals with differences in sex development
Witchel, S. F., & Reyes‐Múgica, M. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70015 · Cited by 6
Hormone replacement in disorders of sex development, and long-term effects
Nordenström, A., Mangone, A., & Mantovani, G. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102022 · Cited by 3
Self-citationTesticular adrenal rest tumors in Indonesian boys with congenital adrenal hyperplasia
Chandra, E., Utari, A., Adriaansen, B. P. H., Westra, D., Ningrum, F. H., Santoso, A. G., van Herwaarden, A. E., & der Grinten, H. L. C. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0026 · Cited by 1
Self-citationEnhancing primary newborn screening efficiency for congenital adrenal hyperplasia with LC-MS/MS/MS
Gaudl, A., Lehmicke, L., Biemann, R., Dittrich, J., & Ceglarek, U. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120482 · Cited by 1
Ventresca, S., Chioma, L., Ruta, R., Mucciolo, M., Parisi, P., Suppiej, A., Loche, S., Cappa, M., & Bizzarri, C. (2025) · Children · doi:10.3390/children12070954 · Cited by 1
Bindellini, D., Michelet, R., Mirasbekov, Y., Lao, Q., Sukin, C., Huisinga, W., Merke, D. P., & Kloft, C. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70086 · Cited by 2
Self-citationOlthof, A., Bouva, M. J., der Grinten, H. L. C., Westra, D., Dekkers, E., Heijboer, A. C., Hannema, S. E., & Boelen, A. (2025) · Archives of Disease in Childhood · doi:10.1136/archdischild-2025-328929 · Cited by 3
Self-citationBacila, I. A., Oberski, L., Li, N., Storbeck, K., Cunliffe, V. T., & Krone, N. P. (2025) · Biology Open · doi:10.1242/bio.061977 · Cited by 3
Self-citationLeptin and adiponectin in children and young persons with congenital adrenal hyperplasia
Bacila, I. A., Lawrence, N., Alvi, S., Cheetham, T. D., Crowne, E. C., Das, U., Dattani, M., Davies, J. H., Gevers, E. F., Keevil, B. G., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf165 · Cited by 1
“1,2 Moreover, while in other forms of adrenal insufficiency the glucocorticoid (GC) treatment aims to merely replace the lacking cortisol, higher doses are required in CAH to normalize the excessive ACTH secretion and hyperandrogenism.”
Self-citationRyabets‐Lienhard, A., Nguyen, J. N., Pickering, T. A., Fraga, N. R., Deras, E. A., Geffner, M. E., & Kim, M. S. (2025) · Hormone Research in Paediatrics · doi:10.1159/000548651 · Cited by 1
Mazloomi, S., Farimani, M. S., & Ahmadi, M. (2025) · Chonnam Medical Journal · doi:10.4068/cmj.2025.61.3.109 · Cited by 1
Lawrence, S. E., Marcadier, J., Auger, S., Bariciak, E., Chakraborty, P. K., Chambers, A., Eagle, S., Kowalskil, M., Marr, A., McIntosh, N., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf157 · Cited by 2
“Given the high false-positive rates on immunoassay screening [1, 17, 18], particularly in premature or unwell infants [19], most screening programs employ a first-tier screen with immunoassay quantification of 17-OHP using BW [20-22] or GA [12] stratification or a combination of both [23, 24].”
Casiraghi, A., Campi, I., Federici, S., Cernigliaro, F., Menabò, S., & Persani, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1726368 · Cited by 1
Evaluation of Potential Hormonal Activities of Ashwagandha ( Withania somnifera )
Vollmer, G., & Brendler, T. (2025) · Phytotherapy Research · doi:10.1002/ptr.70155 · Cited by 6
“One such context is congenital adrenal hyperplasia (CAH), which is a group of autosomal recessive genetic defects in cortisol synthesis (van der Claahsen-Grinten et al. 2022).”
Clinical Application of Steroid Profiles and Their Interpretation in Adrenal Disorders
Ramasamy, I. (2026) · Diagnostics · doi:10.3390/diagnostics16030381 · Cited by 2
Current insights into monitoring of congenital adrenal hyperplasia
Leusink, Q. M., Verploegen, E., Adriaansen, B. P. H., Chin, X., Stikkelbroeck, N. M. M. L., Span, P. N., Sweep, F. C. G. J., Dona, M., van Herwaarden, A. E., & der Grinten, H. L. C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1774145 · Cited by 2
Self-citationHeidtmann, F., Umbreit, S., & Eckoldt, F. (2026) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2026.106051 · Cited by 1
Baets, H. D., Reyns, T., Mazzarino, M., Fiers, T., Eenoo, P. V., & Stove, C. P. (2026) · Talanta · doi:10.1016/j.talanta.2026.130070 · Cited by 2
Zola, M., Han, J. H., Quinodoz, M., Bousquet, E., Matet, A., Kowalczuk, L., Daruich, A., Zhao, M., Ullah, M., Rivolta, C., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.6.5 · Cited by 1
“31,54 In certain cases where 17-OHP levels were not elevated, adrenal insufficiency may have been attributable to exogenous corticosteroid therapy, chronic stress, or environmental factors, such as exposure to endocrine-disrupting chemicals.”
Advances in pharmacological treatment for congenital adrenal hyperplasia
Graves, L. E., & Falhammar, H. (2026) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001583 · Cited by 2
Self-citationClinical practice guidelines "Congenital adrenal hyperplasia in children" with comments
Чугунов, І., Kopylova, I., Kolodkina, A. A., Kalinchenko, N. Y., Vorontsova, M. V., Bezlepkina, O. B., Peterkova, V. A., & Mokrysheva, N. G. (2026) · Problems of Endocrinology · doi:10.14341/probl13767 · Cited by 1
Adriaansen, B. P. H., Utari, A., Chandra, E., Falhammar, H., Bonfig, W., Clemente, M., Lenherr‐Taube, N., Markosyan, R. L., de Miranda, M. C., Span, P. N., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag298
Self-citation
Metadata
- Authors
- Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., Krone, N., Merke, D. P., Miller, W. L., Nordenström, A., Reisch, N., Sandberg, D. E., Stikkelbroeck, N. M. M. L., Touraine, P., Utari, A., Wudy, S. A., & White, P. C.
- Affiliations
- Department of Pediatric Endocrinology, Radboud University Medical Centre, Amalia Childrens Hospital, Nijmegen, The Netherlands
- Northwell Health (US)
- University of Glasgow (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University of Michigan (US)
- Karolinska University Hospital (SE)
- University of Bern (CH)
- Queen Mary University of London (GB)
- Technische Universität Dresden (DE)
- Radboud University Medical Center (NL)
- University Hospital Carl Gustav Carus (DE)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- University of California, San Francisco (US)
- LMU Klinikum (DE)
- Sorbonne Université (FR)
- Diponegoro University (ID)
- Justus-Liebig-Universität Gießen (DE)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- White, Perrin C
- ORCID
- Claahsen - van der Grinten, Hedi L
- Speiser, Phyllis W
- Ahmed, S Faisal
- Arlt, Wiebke
- Auchus, Richard J
- Falhammar, Henrik
- Flück, Christa E
- Guasti, Leonardo
- Huebner, Angela
- Krone, Nils
- Merke, Deborah P
- Miller, Walter L
- Nordenström, Anna
- Reisch, Nicole
- Sandberg, David E
- Touraine, Philippe
- Utari, Agustini
- Wudy, Stefan A
- White, Perrin C
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2021-05-07
- Volume
- 43
- Issue
- 1
- Pages
- 91-159
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W4229036110
- Semantic Scholar
- 1867a4639fab9f23f14102ccc6107c07963e64dc
- Cited by
- 556
- References
- 831
- Citations by year
- 2026: 102 · 2025: 125 · 2024: 149 · 2023: 97 · 2022: 68 · 2021: 14
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Endocrine Reviews (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institutes of Health (U01-HD083493)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, CYP21A2 mutations, cortisol production, steroidogenic pathway, newborn screening, steroid profiling, genotyping, cell therapy, gene therapy, long-term outcomes, disease registries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.